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Abstract
Background: The Plasmodium falciparum pre-erythrocytic stage candidate vaccine RTS,S is being developed for protection
of young children against malaria in sub-Saharan Africa. RTS,S formulated with the liposome based adjuvant AS01E or the
oil-in-water based adjuvant AS02D induces P. falciparum circumsporozoite (CSP) antigen-specific antibody and T cell
responses which have been associated with protection in the experimental malaria challenge model in adults.
Methods: This study was designed to evaluate the safety and immunogenicity induced over a 19 month period by three
vaccination schedules (0,1-, 0,1,2- and 0,1,7-month) of RTS,S/AS01E and RTS,S/AS02D in children aged 5–17 months in two
research centers in Ghana. Control Rabies vaccine using the 0,1,2-month schedule was used in one of two study sites.
Results: Whole blood antigen stimulation followed by intra-cellular cytokine staining showed RTS,S/AS01E induced CSP
specific CD4 T cells producing IL-2, TNF-a, and IFN-c. Higher T cell responses were induced by a 0,1,7-month immunization
schedule as compared with a 0,1- or 0,1,2-month schedule. RTS,S/AS01E induced higher CD4 T cell responses as compared
to RTS,S/AS02D when given on a 0,1,7-month schedule.
Conclusions: These findings support further Phase III evaluation of RTS,S/AS01E. The role of immune effectors and
immunization schedules on vaccine protection are currently under evaluation.
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Introduction
Malaria, caused by the protozoan parasite Plasmodium falciparum,
affects millions of people annually. Infants and young children in
Africa carry most of the disease burden. P. falciparum has a complex
life cycle including several developmental stages in its human host.
The RTS,S malaria candidate vaccine, which has recently entered
Phase III testing, targets the P. falciparum circumsporozoite protein
(CSP), a pre-erythrocytic stage antigen. Implemented in the
Expanded Program of Immunization (EPI), together with existing
control measures such as wide spread use of insecticide treated
nets, vector control and use of new generation anti-malaria drugs,
RTS,S may contribute to sustained malaria control.
The vaccine antigen contains the central tandem repeats and
carboxy-terminal regions of CSP fused to the N-terminal of
hepatitis B virus surface antigen. Combination of this fusion
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protein with native hepatitis B surface antigen results in the
spontaneous formation of RTS,S virus-like particles [1]. This
antigen formulated with the AS02 adjuvant induces CSP specific
adaptive immune responses and protection against infection in
controlled parasite challenge studies [2–5] as well in semi-immune
adults, children and infants living in malaria-endemic regions [6–
11]. The AS02 adjuvant is based on an oil-in-water emulsion
combined to the TLR4 ligand monophosporyl lipid A (MPL) and
the QS21 saponin fraction of Quillaja saponaria [1]. A new RTS,S
formulation containing the AS01 adjuvant and consisting of MPL,
QS21 and liposomes was recently selected as an alternative to
RTS,S/AS02 on the basis of its ability to induce comparable, or
better, CSP-specific antibody responses and greater T cell
responses in small animal models and non-human primates than
did AS02 [12,13]. This effect was confirmed in a Phase IIa
controlled parasite challenge study performed in malaria naı¨ve
adults at the Walter Reed Army Institute of Research where,
compared to RTS,S/AS02, RTS,S/AS01 was shown to be well
tolerated, to induce strong humoral and cellular immune
responses, and to improve protection against P. falciparum
challenge [5]. Efficacy of RTS,S/AS01E (the pediatric formulation
of RTS,S/AS01) against malaria was then evaluated in children,
with favourable results [14], and the possibility to safely co-
administer RTS,S/AS01E and EPI vaccines has been shown [15].
Both humoral and cellular immune responses play a key role in
protection against Plasmodium infection in mice [16–21]. However,
the relevance of these observations to the host-parasite relationship
in humans remains to be demonstrated. Recent evidence indicates
that, in adults, protection is associated with high titers of CSP-
specific antibodies and CD4 T cell responses [5]. As pediatric
populations are particularly susceptible to malaria, it is important to
investigate humoral and cellular immune responses in a younger age
group to provide a better understanding of the immune mechanisms
which mediate protection following RTS,S vaccination.
The present study was designed to document the safety and
immunogenicity of RTS,S/AS01E and RTS, S/AS02D (the
pediatric formulation of RTS,S/AS02) in 5–17 month old children
at two different sites in Ghana. Three schedules selected on the
basis of compatibility with the existing EPI vaccination program
were evaluated for induction of anti-CSP antibodies and T cell
responses. Results of safety and humoral immunogenicity
evaluations have been reported previously [22]. Briefly, both
RTS,S/AS02D and RTS,S/AS01E were well tolerated and
induced high titers of anti-CSP and anti-HBs antibodies.
Recipients of RTS,S/AS01E had higher peak anti-CSP antibody
responses for all 3 schedules than did recipients of RTS,S/AS02D.
Three-dose schedules induced higher antibody levels than 2-dose
schedules. The peak antibody response following a 0,1,2-month
schedule was higher than following a 0,1,7-month schedule, but
area under the curve analyses of anti-CSP antibodies for the
overall study period were comparable between the 0,1,2- and
0,1,7-month schedules for both vaccine formulations. T-cell
responses, using whole blood antigen-stimulation followed by
intracellular cytokine staining, are reported here.
Materials and Methods
The supporting CONSORT checklist for this trial is available as
supporting information; see Checklist S1. The protocol of this trial
was posted with a previous publication (Protocol S1 [22]).
Ethics statement
The protocol was approved by relevant ethical and institutional
review boards as described previously [22]. The trial was
undertaken according to the International Conference on
Harmonization, Good Clinical Practice guidelines and was
monitored by GlaxoSmithKline (GSK) Biologicals. The study
was overseen by a formally constituted Data Safety Monitoring
Board (DSMB) operating under a charter. Written informed
consent was obtained from each child’s parent(s) or guardian(s)
before study procedures were initiated. Illiterate parents or
guardians indicated consent using a thumbprint, and a signature
was obtained from a literate witness.
Study design and sampling
The design of this trial [http://clinicaltrials.gov:
NCT00360230] and CONSORT flowchart have been described
in detail previously [22]. No changes were made to the protocol
after ethical approval. Briefly, the trial was a Phase II randomized,
controlled, partially-blind study. A total of 540 eligible subjects
were randomly assigned to one of three study groups in each study
site (Figure 1). In one site rabies vaccine (Purified chick embryo
cell-culture rabies vaccine; Chiron Behring GmbH, Marburg,
Germany), administered following a 0,1,2-month schedule, was
used as a control. Blood samples for assessment of cell-mediated
immune (CMI) responses were collected one month after the last
vaccine dose in each vaccination schedule (peak response) and at
month 19 of the study. The study was conducted in two locations
in Ghana, about 200 km apart: one coordinated from Kumasi
Centre for Collaborative Research/School of Medical Sciences
(KCCR/SMS), Kumasi, with the field site in the town of Agogo
and clinical activities centered at the Agogo Presbyterian Hospital,
and the other one in the Kintampo area, with clinical activities
centered at the Kintampo Health Research Centre (KHRC) and
Kintampo Hospital. Malaria transmission in both areas is intense
and perennial. Insecticide treated nets were distributed to potential
study participants at screening.
Detection of anti-CSP humoral responses
Serum antibodies to the NANP repeat region of CSP (B cell
epitope) were measured by a standard, validated enzyme-linked
immunosorbent assay (ELISA) using plates adsorbed with the
recombinant antigen R32LR that contains the sequence
[NVDP(NANP)152LR], at a GSK validated laboratory (CEVAC,
University of Ghent, Belgium). Titers were calculated using a
reference standard curve with a 4 parameter logistic fitting
Figure 1. Schematic representation for evaluation of CSP
specific T cell responses. Triangles represent timing of vaccination
for 0,1-, 0,1,2- and 0,1,7-month schedules (RTS,S/AS01E, RTS,S/AS02D or
Rabies vaccine); arrows represent timing of blood sampling. In both
research centers, each study group included 45 individuals.
doi:10.1371/journal.pone.0018891.g001
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algorithm and expressed in EU/ml, with cut-off for seropositivity
of 0.5 EU/ml [23].
Whole blood intracellular cytokine staining and flow
cytometry
Intracellular cytokine staining (ICS) was used to assess cell-
mediated immune responses, using an adaptation of previously
described methods [24]. Immediately after blood collection in
Lithium-heparin tubes, whole blood samples were stimulated in
vitro with a pool of 15-mer peptides overlapping by 11 amino acids
and covering the CSP antigen in RTS,S (1.25 mg/ml), medium
(negative control) or phytohemagglutin A (PHA, positive control),
in the presence of anti-CD28 and anti-CD49d antibodies (BD
Biosciences, Belgium). After 2 hours of incubation at 37uC,
Brefeldin A (BD Biosciences) was added, and samples were
incubated overnight. Red blood cells were then lysed and
remaining cells were washed, fixed and frozen at 280uC until
subsequent analysis. After thawing, cells were washed and stained
using peridinin-chlorophyll (PerCP)-conjugated anti-CD4 (BD
Biosciences) and allophycocyanin (APC)-H7 conjugated anti-
CD8 antibodies (BD Biosciences). Cells were then fixed and
permeabilized with the Cytofix/Cytoperm buffer kit (Pharmin-
gen), and stained with APC conjugated anti-IL-2 (Pharmingen),
fluorescein-isothiocyanate (FITC)-conjugated anti-IFN-c (Phar-
mingen), phycoerythrin (PE) cyanin-7 (Cy7)-conjugated anti-TNF-
a (Pharmingen) and PE-conjugated anti-CD154 (CD40L) (Phar-
mingen). Cells were washed, re-suspended in fetal-calf-serum
(FCS)-containing phosphate buffered saline (PBS) and analyzed on
a BDTM LSR II flow cytometer (BD Biosciences). Analysis was
performed using BDTM Diva software (BD Biosciences). The ICS
results were expressed as the number of CSP-specific CD4/CD8 T
cells expressing IL-2, IFN-c, TNF-a or CD40L per million CD4/
CD8 T cells. The gating strategy and an illustrative example of
cytokine response are shown in Figure 2. The analysis of CD4 T
cell polyfunctionality was conducted using FlowJo software (Tree
Star Inc).
Statistical analysis
The analysis of CMI responses was performed on the ATP
cohort for immunogenicity. The frequency of CSP-specific CD4,
CD8 T cells expressing at least CD40L, IFN-c, IL-2 or TNF-a was
summarized for each group at peak (one month post final dose)
and at month 19. Descriptive statistics (mean, median, quartiles)
were tabulated by group and, within schedules, a comparison of
adjuvants was made using Wilcoxon Rank Sum test. The between
schedule comparison and the RTS,S/AS01E versus rabies
comparison were done using the mixed model procedure adjusted
for multiple comparisons using the Bonferroni method to correct
for type I error. A responder was defined as a subject with an
outcome that was equal or greater than the geometric mean + 3
standard deviations (on the log 10 scale) of background stimulation
for each cytokine. Spearman rank correlations were used to assess
the correlations between the log of CSP-specific CD4 IL-2 and
CD4 TNF-a responses for each schedule and both vaccine
formulations with antibody levels at peak (one month post final
dose) and at month 19.
Results
Detection of RTS,S/AS01E-induced CSP-specific CD4 T cell
responses in infants and young children
As a benchmark, the RTS,S/AS01E T cell response was first
compared to the response seen in the rabies group. Only data from
Kintampo are presented here, as rabies vaccine was not
administered in Agogo. Figure 3 presents the frequency of CSP-
specific CD4 T cells expressing at least IL-2, TNF-a or IFN-c.
Compared to the rabies group, responses are modestly but
significantly higher in the RTS,S/AS01E vaccinated group at peak
(one month post last dose) and at month 19 of the study. There
was no significant difference in the expression of CD40L between
both groups at either time point. No vaccine-induced CSP-specific
CD8 T cell responses were detected (data not shown).
A more detailed characterization of cytokine expression by
CSP-specific CD4 T cells in the RTS,S/AS01E vaccinated
children from Kintampo showed that at one month post third
vaccination the majority of CSP-specific CD4 T cells were
expressing IL-2 only. Polyfunctional CSP-specific CD4 T cells
were essentially IL-2+ TNF-a+ CD4 T cells and to a lesser extent
CD40L+ IL-2+ TNF-a+ CD4 T cells (Figure 4).
Comparison of CSP-specific CD4 T cell responses induced
by RTS,S/AS01E and RTS,S/AS02D
For the comparison of CSP-specific CD4 T cell responses
induced by RTS,S/AS01E and RTS,S/AS02D, data from the two
study centers for the 0,1- and 0,1,7-month schedules were pooled.
Data for the 0,1,2-month schedule are not shown as RTS,S/
AS02D was not administered on a 0,1,2-month schedule in
Kintampo.
When administered in a three dose regimen following a 0,1,7-
month schedule, RTS,S/AS01E induced higher CSP-specific IFN-
c+ CD4 T cell responses as compared to RTS,S/AS02D one
month after the last vaccination, but not at month 19. The
frequency of IL-2+ and TNF-a+ CD4 T cells was greater in
RTS,S/AS01E recipients than in RTS,S/AS02D recipients at
month 19, but not one month after vaccination (Table 1).
When considering the two dose regimen (0,1-month), no
marked differences in the CSP-specific T cell response induced
by the two vaccine formulations were seen, other than a higher
frequency of CD40L+ CD4 T cell at month 19 after RTS,S/
AS02D vaccination.
Comparison of CSP-specific CD4 T cell responses
between vaccination schedules
An important objective of this study was the comparison of
different vaccination schedules compatible with integration into
the existing EPI vaccination program. In a previous report we
have shown that anti-CSP antibody titers were higher in groups
vaccinated with RTS,S/AS01E using a three-dose rather than two-
dose regimen [22]. CD4 T cell responses following vaccination
according to different vaccination schedules with RTS,S/AS01E
(the formulation evaluated according to all 3 schedules in both
study centers), are presented in Table 2. When considering
responses one month after the last vaccination, no substantial
differences were observed between a 0,1-month vaccination
schedule and a 0,1,2month vaccination schedule, but compared
to both other vaccination schedules, the 0,1,7-month schedule
induced higher CD4 T cell responses. At month 19 however, only
the TNF-a response was still higher in the 0,1,7-month schedule as
compared to the 0,1-month schedule. Similar results were
observed for the RTS,S/AS02D formulation, when considering
data from Agogo only (where RTS,S/AS02D was evaluated
according to all 3 vaccine schedules, data not shown).
Relationship between CSP-specific CD4 T cell responses
and anti-CSP antibody titers
As IL-2 and TNF-a were the cytokines most clearly activated
following antigen re-stimulation of whole blood from RTS,S/AS01E
CMI to RTS,S/AS01E and RTS,S/AS02D in Children
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Figure 2. Whole-blood intracellular cytokine detection by flow cytometry. Whole-blood intracellular cytokine detection by flow cytometry
was performed following overnight stimulation with medium (negative control), CSP and PHA (positive control). (A) CD4 or CD8 T cells were
identified from a lymphocyte gate on an SSC-FSC plot. (B) IL-2+, TNF-a+, IFN-c+, and CD40-ligand (not shown) CD4 T cells and CD8 T cells (not shown)
were counted. The unstimulated sample (medium) shows background levels of cytokine production, while the stimulation with PHA (positive control)
shows strong production of IL-2, TNF-a, or IFN-c by CD4 T cells. The CSP stimulated illustrative sample from an RTS,S/AS01E vaccinated individual
shows production of IL-2, TNF-a, and IFN-c by CD4 T cells.
doi:10.1371/journal.pone.0018891.g002
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Figure 3. Frequency of CSP-specific CD4 T cells expressing at least IL-2, TNF-a or IFN-c. CSP-specific CD4 T cell responses in infants and
children aged 5–17 months from Kintampo, vaccinated with RTS,S/AS01E or rabies vaccine according to a 0,1,2-month immunization schedule.
Results are expressed as the median (with Q1 and Q3) number of CSP-specific CD4 T cells per 106 CD4 T cells. The number of subjects per group and
percentage responders (defined as a response that was equal or greater than the geometric mean + 3 standard deviations (on the log 10 scale) of
background stimulation) is indicated. P-values were calculated using the Wilcoxon Rank Sum test. *** P,0.001, ** P,0.01, * P,0.05.
doi:10.1371/journal.pone.0018891.g003
Figure 4. Polyfunctional profiles of CSP-specific CD4 T cells one month post last immunization. Polyfunctional profiles of CSP-specific
CD4 T cells expressing any combination of immune markers among IL-2, TNF-a, IFN-c, and CD40L in infants and children aged 5–17 months from
Kintampo, vaccinated with RTS,S/AS01E or rabies vaccine according to a 0,1,2-month immunization schedule. Data are represented as background
subtracted geometric mean number of CSP-specific CD4 T cells expressing any combination of IL-2, TNF-a, IFN-c, and/or CD40L per 106 CD4 T cells,
with 95% CI (A). The pie chart represents the proportion of CSP-specific CD4 T cells expressing 1, 2, 3 or 4 immune markers amongst IL-2, TNF-a, IFN-c,
and CD40L from RTS,S/AS01E recipients (B).
doi:10.1371/journal.pone.0018891.g004
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or RTS,S/AS02D vaccinated infants and young children, the
associations between CSP-specific IL-2+ and TNF-a+ CD4 T cell
responses and the CSP-specific antibody responses were investigated
using Spearman rank correlation index. As presented in detail in
Table 3, weak but statistically significant or borderline correlations
were found between peak IL-2+ and TNF+ CD4 T cell responses and
serum anti-CSP antibodies at the time of the peak response and at
month 19 in children in the RTS,S/AS01E 0,1,2-month schedule
and in the RTS,S/AS02D 0,1,7-month schedule groups.
Discussion
In this study we have investigated antigen-specific T cell
responses in infants and young children aged 5–17 months,
vaccinated with RTS,S/AS01E or RTS,S/AS02D according to
three different immunization schedules. The rationale for
investigating cellular responses to the CSP antigen in field studies
is based on a growing body of evidence suggesting an important
role of vaccine induced T cell responses targeting the pre-
Table 1. Adjuvant comparison; CSP-specific CD4 T cell responses induced by RTS,S/AS01E and RTS,S/AS02D administered at 0,1-
and 0,1,7-months (data pooled for both study sites) at peak (one month post last vaccination) and at study end (month 19).
RTS,S/AS01E RTS,S/AS02D
Vaccine
schedule Timepoint Marker N (%) M (Q1–Q3) N (%) M (Q1–Q3) p-value
0,1 M2 IL-2 77 (52) 133 (20–391) 80 (45) 86 (24–374) 0.71
TNF-a 77 (21) 38 (1–132) 80 (13) 26 (1–135) 0.62
IFN-c 77 (0) 1 (1–20) 80 (0) 1 (1–14) 0.1
CD40L 77 (9) 1 (1–24) 80 (8) 1 (1–26) 0.95
M19 IL-2 73 (19) 42 (1–96) 75 (27) 48 (1–151) 0.99
TNF-a 73 (10) 14 (1–57) 75 (9) 18 (1–65) 0.9
IFN-c 73 (1) 1 (1–24) 75 (1) 1 (1–15) 0.89
CD40L 73 (11) 1 (1–39) 75 (20) 29 (1–77) 0.0012
0,1,7 M8 IL-2 70 (76) 305 (68–961) 73 (71) 186 (43–852) 0.59
TNF-a 70 (76) 187 (57–667) 73 (74) 162 (53–439) 0.68
IFN-c 70 (43) 57 (1–115) 73 (27) 20 (1–79) 0.013
CD40L 70 (61) 156 (25–417) 73 (58) 119 (35–235) 0.37
M19 IL-2 73 (53) 171 (23–365) 70 (36) 56 (1–210) 0.0083
TNF-a 73 (30) 70 (14–211) 70 (17) 36 (1–85) 0.015
IFN-c 73 (1) 13 (1–44) 70 (3) 12 (1–27) 0.35
CD40L 73 (32) 27 (1–116) 70 (24) 15 (1–79) 0.34
N (%): Number of subjects per group and percentage responders (defined as a response$ geometric mean + 3 standard deviations (on the log 10 scale) of background
stimulation).
M (Q1–Q3): Results are expressed as the median (Q1 and Q3) number of CSP-specific CD4 T cells per 106 CD4 T cells.P-values for comparison of RTS,S/AS01E and RTS,S/
AS02D were calculated using the mixed model procedure adjusted for multiple comparison using the Bonferroni method to correct for type I error.
doi:10.1371/journal.pone.0018891.t001
Table 2. Schedule comparison; CSP-specific CD4 T cell responses induced by RTS,S/AS01E administered at 0,1-, 0,1,2- or 0,1,7-
months (data pooled over both study sites) at peak (one month post last vaccination) and at study end (month 19).
Timepoint Marker
0,1 schedule
Median (Q1–Q3)
0,1,2 schedule
Median (Q1–Q3)
0,1,7 schedule
Median (Q1–Q3)
p-value
0,1 vs 0,1,2
p-value
0,1 vs 0,1,7
p-value
0,1,2 vs 0,1,7
Peak IL-2 133 (20–391) 83 (1–372) 305 (68–961) 1 0.32 0.031
TNF-a 38 (1–132) 35 (1–136) 187 (57–667) 1 0.0025 0.0001
IFN-c 1 (1–20) 1 (1–37) 57 (1–115) 0.7 ,0.0001 ,0.0001
CD40L 1 (1–24) 1 (1–22) 156 (25–417) 1 ,0.0001 ,0.0001
Month 19 IL-2 42 (1–96) 79 (1–256) 171 (23–365) 1 0.072 0.89
TNF-a 14 (1–57) 32 (1–104) 70 (14–211) 1 0.0028 0.46
IFN-c 1 (1–24) 1 (1–40) 13 (1–44) 1 0.24 1
CD40L 1 (1–39) 16 (1–72) 27 (1–116) 0.84 0.058 1
M (Q1–Q3): Results are expressed as the median (Q1 and Q3) number of CSP-specific CD4 T cells per 106 CD4 T cells.
P-values: Comparison were done using the mixed model procedure adjusted for multiple comparison using the Bonferroni method to correct for type I error.
doi:10.1371/journal.pone.0018891.t002
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erythrocytic stage of malaria infection in the protection provided.
This was initially demonstrated in experimental animal models
[20]. In human adults, an association between vaccine efficacy and
both anti-CSP humoral and CD4 T cell response was shown in
individuals vaccinated with RTS,S/AS01 and RTS,S/AS02 who
then went through an experimental sporozoite challenge [5].
Other vaccine candidates target protection from CD8 responses
targeting pre-erythrocytic antigens [25]
This study has shown that RTS,S/AS01E vaccination of infants
and children induces CSP-specific CD4 T cells expressing IL-2,
TNF-a or IFN-c. These results are in line with previously shown
RTS,S/AS01 induced responses in adults [5]. Quantitative
differences and the absence of CD40-L induction may be related
to physiologic differences, or to the fact that the pediatric assay
uses whole blood antigen stimulation while PBMC were used in
adults. As in most other RTS,S vaccination studies, CSP-specific
CD8 T cells were not detected, but it is possible that they may not
be detected in peripheral blood one month after vaccination, while
still playing a role in vivo.
Whether activated CSP-specific CD4 T cells have a direct anti-
parasite effector role, or whether they act indirectly by supporting
other effector functions remains to be demonstrated. A direct role of
activated CD4 T cells against infected liver cells is possible, as
several cell types present in the liver, such as Kupffer cells, liver
dendritic cells, endothelial cells and hepatocytes themselves can
express MHC Class II molecules necessary for antigen presentation
to CD4 T cells [20]. CD4 T cells, through the expression of TNF-a
and IFN-c, could contribute to the elimination of intracellular
Plasmodia [18,20,26], or through other yet uncharacterized effector
mechanism(s). CD4-derived IL-2 could also help NK or CD8 T cells
to clear parasites as has been shown in blood-stage infection [27].
Whether or not they display intrinsic protective effector
functions, CD4 T cells are likely to contribute to antibody
production. In this study, weak but significant correlations were
found between the anti-CSP CD4 T cell and antibody responses.
This observation is in line with the well known helper T cell
function, providing help to B cells, promoting antibody class
switch, affinity maturation and induction of memory B cells
[28,29], thus potentially contributing to antibody-mediated
protection [30]. IL-2 production by CSP-specific CD4 T cells
could play an important role in the maintenance of circulating
anti-CSP antibodies [31].
This study and previous trials in adults and children showed
that the AS01 formulated RTS,S vaccine induces higher anti-CSP
antibody responses than the AS02 formulation [5,22,32,33]. In a
trial in malaria-naı¨ve American adults, superior T cell responses,
humoral responses and a trend towards higher protection against
P. falciparum infection in the experimental challenge model were
also shown after RTS,S/AS01 vaccination, as compared to
RTS,S/AS02 [5]. In the study described here, the adjuvant
comparison generally favored RTS,S/AS01E when considering
the IFN-c response at one month after the last vaccination and the
IL-2 and TNF-a response at study end in the 0,1,7-month
schedule. This was not seen when comparing the vaccine
formulations in the 0,1-month schedule. Overall, when consider-
ing the humoral [22] and cellular immunogenicity data, the results
from this trial are supportive of the selection of RTS,S/AS01E for
further Phase III evaluation.
For a new public health intervention in Sub-Saharan Africa,
implementation into an existing delivery program is a key success
factor. For a new vaccine, it is important that the immunization
schedule be compatible with the existing EPI program. In this study,
three immunization schedules were evaluated: a 0,1,2-month
schedule that could be delivered together with the diphtheria,
tetanus, pertussis, Haemophilus influenza type b and hepatitis B
vaccines (DTP-HepB/Hib), a 0,1-month schedule which would
have the advantage of only two doses, and a 0,1,7-month schedule
with a delayed third dose that could be administered with the
measles vaccination in the infant EPI program.
A study of 1 to 4 year old children in Gabon showed that anti-CSP
antibody levels after three doses of RTS,S/AS01E or RTS,S/AS02D
were higher than those obtained after two doses [32]. This was
confirmed in the present trial, as presented in the initial report [22],
and in a study of RTS,S/AS01E administered to infants together
with EPI vaccines [15]. A three dose immunization schedule was
therefore selected for further RTS,S/AS01E evaluation.
In the present study, although the humoral responses induced
by a 0,1,2- and a 0,1,7-month schedule were comparable in terms
of area under the curve for anti-CSP antibody titer evolution over
time, the peak (one month post last dose) antibody titer following a
0,1,2-month immunization schedule was superior to the peak
Table 3. Evaluation of the correlation between CSP-specific IL-2+ and TNF-a+ CD4 T cell responses one month post last vaccination
(peak) with anti-CSP antibody titers at peak and at month 19 (analysis of data pooled over both study sites).
RTS,S/AS01E RTS,S/AS02D
Analysis of correlation between peak CD4 T cell response and peak antibody response
Schedule 0,1 0,1,2 0,1,7 0,1 0,1,2 0,1,7
IL-2 0.07125
(p = 0.54)
0.25574
(p = 0.028)
0.07924
(p = 0.51)
0.20485
(p = 0.068)
20.11734
(p = 0.47)
0.28147
(p = 0.016)
TNF-a 0.27930
(p = 0.014)
0.22607
(p = 0.053)
0.01716
(p = 0.89)
0.18516
(p = 0.1)
0.05244
(p = 0.75)
0.35847
(p = 0.0018)
Analysis of correlation between peak CD4 T cell response and M19 antibody response
IL-2 0.32018
(p = 0.0051)
0.37385
(p = 0.0011)
0.18822
(p = 0.12)
0.28242
(p = 0.015)
0.15637
(p = 0.34)
0.27181
(p = 0.022)
TNF-a 0.35850
(p = 0.0016)
0.31764
(p = 0.0062)
0.16431
(p = 0.17)
0.24323
(p = 0.037)
0.25317
(p = 0.12)
0.32417
(p = 0.0058)
The relationship between CSP-specific CD4 T cell response and CSP-specific antibody level was analyzed using Spearman’s rank correlation and associated p-values are
shown.
doi:10.1371/journal.pone.0018891.t003
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following a 0,1,7-month immunization schedule [22]. When
considering the CD4 T cell response as reported here, no
differences were detected between children who received
RTS,S/AS01E on a 0,1- or 0,1,2-month schedule, but the 0,1,7-
month induced higher responses one month after the last
vaccination. The differences between the 0,1,2- and the 0,1,7-
month schedules were no longer detected at month 19. The
physiological basis for better peak antibody responses with a 0,1,2-
over a 0,1,7-month schedule, but opposite observation when
considering CD4 T cell responses, are unclear. Delaying the last
immunization dose is classically described as being favorable to
immunogenicity in young children [34], as seen here with CD4 T
cell responses but not antibody responses. The clinical significance
of these observations remains unclear. Ongoing studies are
evaluating respective vaccine efficacy of a 0,1,2- and a 0,1,7-
month RTS,S/AS01E infant immunization schedule.
Altogether, the CMI data reported in this study combined with
the anti-CSP antibody responses in children described previously
[15,22,32] support the ongoing Phase III evaluation of protective
efficacy and immunogenicity of RTS,S/AS01E administered using
a three dose regimen.
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